Management of ST-segment elevation myocardial infarction in EDs

American Journal of Emergency Medicine

Volumn 26, Issue 1, 2008, Pages 91-100

  Diercks, Deborah B ^a   Kontos, Michael C ^b   Weber, Jim E ^c   Amsterdam, Ezra A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; ANALGESIC AGENT; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DALTEPARIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MORPHINE; NITRATE; PHOSPHODIESTERASE INHIBITOR; RETEPLASE; SILDENAFIL; STREPTOKINASE; TENECTEPLASE; TIROFIBAN;

ACUTE HEART INFARCTION; ARTICLE; BLEEDING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; ELECTROCARDIOGRAM; EMERGENCY WARD; FIBRINOLYSIS; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; HYPOTENSION; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-ANTAGONISTS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; COMBINED MODALITY THERAPY; EMERGENCY SERVICE, HOSPITAL; ENOXAPARIN; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; OXYGEN; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; STREPTOKINASE; THROMBOLYTIC THERAPY;

EID: 37049036894     PISSN: 07356757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajem.2007.06.014     Document Type: Article

References (50)

1. McCaig L.F., and Burt C.W. National Hospital Ambulatory Medical Care Survey: 2002 emergency department summary. Adv Data 340 (2004) 1-34
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). J Am Coll Cardiol 44 (2004) 671-719
3. D2B Alliance for Quality guidelines applied in practice. Available at: www.d2balliance.com. Retrieved March 8, 2007.
4. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 7 (2006) e166-e286
5. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
6. Keeley E.C., and Grines C.L. Primary percutaneous coronary intervention for every patient with ST-segment elevation myocardial infarction: what stands in the way?. Ann Intern Med 141 (2004) 298-304
7. Nallamothu B.K., and Bates E.R. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything?. Am J Cardiol 92 (2003) 824-826
8. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
9. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
10. Ignarro L.J. After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A 99 (2002) 7816-7817
11. Kawamoto J.H., Brien J.F., Marks G.S., and Nakatsu K. A comparative study of glyceryl trinitrate biotransformation and glyceryl trinitrate induced relaxation in bovine pulmonary artery and vein. Can J Physiol Pharmacol 65 (1987) 1146-1150
12. Chen L.Y., Mehta P., and Mehta J.L. Platelet inhibitory effect of nitroglycerin in platelet-rich plasma: relevance of glutathione-S-transferases in plasma. J Investig Med 44 9 (1996) 561-565
13. Liberts E.A., Willoughby S.R., Kennedy J.A., and Horowitz J.D. Effects of perhexiline and nitroglycerin on vascular, neutrophil and platelet function in patients with stable angina pectoris. Eur J Pharmacol 560 (2007) 49-55
14. Yusuf S., Collins R., MacMahon S., and Peto R. Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet 1 (1988) 1088-1092
15. Flaherty J.T. Role of nitrates in acute myocardial infarction. Am J Cardiol 70 (1992) 73B-81B
16. Grossmann M., Abiose A., Tangphao O., Blaschke T.F., and Hoffman B.B. Morphine-induced venodilation in humans. Clin Pharmacol Ther 60 (1996) 554-560
17. Meine T.J., Roe M.T., Chen A.Y., Patel M.R., Washam J.B., Ohman E.M., et al., CRUSADE Investigators. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J 149 6 (2005) 1043-1049
18. First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
19. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Patient population. Am J Cardiol 56 (1985) 10G-14G
20. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial. N Engl J Med 320 (1989) 618-627
21. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1622-1632
22. Eagle K.A., Goodman S.G., Avezum A., Budaj A., Sullivan C.M., Lopez-Sendon J., and GRACE Investigators. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 359 (2002) 373-377
23. Seitz R., Pelzer H., Immel A., and Egbring R. Prothrombin activation by thrombolytic agents. Fibrinolysis 7 (1993) 109-115
24. Hirsh J., and Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl 3 (2004) 188S-203S
25. Warkentin T.E., Levine M.N., Hirsh J., Horsewood P., Roberts R.S., Gent M., et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 332 (1995) 1330-1335
26. Klein W., Kraxner W., Hödis R., Steg G., Budaj A., Gulba D., et al. Improved survival and reduced bleeding with low-molecular-weight heparin across all acute coronary syndrome subsets: findings from the global registry of acute coronary events. J Am Coll Cardiol 39 Suppl 2 (2002) 444
27. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 336 (1990) 65-71
28. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 339 (1992) 753-770
29. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
30. Kontny F., Dale J., Abildgaard U., and Pedersen T.R. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 30 (1997) 962-969
31. Frostfeldt G., Ahlberg G., Gustafsson G., et al. Low molecular weight heparin (dalteparin) as adjuvant treatment to thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 33 (1999) 627-633
32. Simoons M., Krzeminska-Pakula M., Alonso A., et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur Heart J 23 (2002) 1282-1290
33. Ross A.M., Molhoek P., Lundergan C., et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104 (2001) 648-652
34. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
35. Antman E.M., Louwerenburg H.W., Baars H.F., et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 105 (2002) 1642-1649
36. Theroux P., and Welsh R.C. Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. Am J Cardiol 91 (2003) 860-964
37. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108 (2003) 135-142
38. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 354 (2006) 1477-1488
39. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295 (2006) 1519-1530
40. White H. Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 358 (2001) 1855-1863
41. Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Plavix product information. Accessed: http://products.sanofi-aventis.us/plavix/plavix.pdf [14 January 2006].
42. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294 (2005) 1224-1232
43. Montalescot G., Barragan P., Wittenberg O., et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
44. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
45. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
46. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101 (2000) 2788-2794
47. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 99 (1999) 2720-2732
48. Giugliano R.P., Roe M.T., Harrington R.A., et al. Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the integrilin and tenecteplase in acute myocardial infarction (INTEGRITI) Phase II Angiographic Trial. J Am Coll Cardiol 41 (2003) 1251-1260
49. Rebeiz A.G., Johanson P., Green C.L., et al. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol 95 (2005) 611-614
50. Topol E.J., and GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357 (2001) 1905-1914